A drug used to treat MS could be repurposed to treat infections in cystic fibrosis patients
For inhaler technology to evolve, questions about efficacy must be answered
Regulating the production of alpha-synuclein may be a new approach for treating Parkinson’s
Will premature infants soon be able to return to a uterine environment to finish their development?
A biomedical device can give damaged lungs a breath of fresh air and make them donor-ready
Tightly controlled efficacy studies can’t predict real-word effectiveness
What does it take to create a competitive companion diagnostic? Bharathi Vennapusa outlines her role in the development and approval of the ALK CDx – a fully-automated immunohistochemistry assay that identifies lung cancer patients who may be eligible for treatment with Pfizer’s Xalkori (crizotinib).
Sitting Down With… Julian Solway MD, Walter L. Palmer Distinguished Service Professor - Medicine and Pediatrics, Director - Institute for Translational Medicine, Dean for Translational Medicine, University of Chicago, USA.
Better understanding of human biology presents us with an opportunity to combat disease on two fronts – targeting individual variation on one hand and universal mechanisms on the other.
Send me the latest from The Translational Scientist.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.